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During an investigation of the cellular basis of the immunodeficiency in patients 
with Hodgkin's disease, long-lasting immunologic alterations were demonstrated after 
lymphoid irradiation  (1). Alterations which were not present in unirradiated patients 
included  a  profound  T  lymphopenia and  marked  reduction  in  the  in  vitro mixed 
leukocyte reaction (MLR) a of peripheral blood lymphocytes to allogeneic cells. It was 
subsequently demonstrated  that  fractionated  total  lymphoid irradiation  (TLI) pro- 
duced  potent  immunosuppression in  normal laboratory animals  (2).  Preparation of 
recipients with TLI allowed for successful bone marrow transplantation across major 
histocompatibility  barriers  in  mice,  rats,  and  dogs  (3-5).  Permanent  chimerism 
developed  without  graft-versus-host  disease.  Experiments  designed  to  look  at  the 
mechanism of graft survival revealed that allogeneic marrow cells, as well as heterol- 
ogous  soluble  antigens,  injected  into  animals  after TLI evoked a  state of antigen- 
specific tolerance rather than  immunity  (3,  6).  An active role for suppressor T  cells 
has been demonstrated (6). 
NZB/NZW F1 mice spontaneously develop an autoimmune disease characterized 
by anti-nuclear antibodies and a fatal immune complex glomerulonephritis (7). These 
features  are  similar  to  those  seen  in  human  systemic  lupus  erythematosus  (SLE). 
These  F1  mice  offer  an  excellent  model  in  which  to  study  therapeutic  regimens 
possibly applicable to human disease. Immunologic abnormalities including sponta- 
neous B-cell activation, age-related T-cell suppressor defects, and resistance to toler- 
ance induction  have been implicated in the pathogenesis  (8-11).  Many studies have 
demonstrated the efficacy of immunosuppressive drug therapy before clinical NZB/ 
NZW  disease  appears,  but  few  have  been  effective  in  mice  with  established  or 
advanced disease (12-23). The object of the present study was to determine whether 
TLI could produce a  remission in mice with moderate or advanced disease. Prelimi- 
nary  studies  carried  out  in  a  single  small  group of animals showed  that  TLI can 
suppress the renal disease and markedly increase survival (S.  Slavin and S.  Strober, 
unpublished observations). The experimental results reported here using large groups 
of animals show that TLI was able to decrease the level of proteinuria and anti-DNA 
antibodies, and increase the  1-yr survival from 25% to >90%. 
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Materials and Methods 
Mice.  Parent NZB and NZW mice were obtained from Dr. M. E. Gershwin (University of 
California, Davis, Calif.) and Dr. H. O. McDevitt (Stanford University Medical Center). NZB/ 
NZW hybrids were bred in the animal facilities of the Stanford University Medical Center. 
Only female hybrids were used. 
Irradiation.  TLI was  administered using a  regimen described previously (3). Briefly,  mice 
were anesthetized with pentobarbital for proper positioning in an apparatus that exposed the 
major lymph nodes, thymus, and spleen to the x-ray source.  The skull, lungs, long bones, and 
tail were shielded with lead. A Philips unit (250 kV,  15 mA, Philips Medical Systems,  Inc., 
Shelton, Conn.) was used to deliver 17 fractions of 200 rad each to achieve a total dose of 3,400 
rad during a 3- to 4-wk period. 
Proteinuria.  Proteinuria was  measured with tetrabromphenol paper  (Albustix, Ames Co., 
Inc., Elkhart, Ind.) on freshly expressed urine samples. This colorimetric assay which is relatively 
specific for albumin was graded 1-4  + and approximates protein concentration as follows:  i + 
30 mg%,  2  + ~  I00 mg%, 3  + ~  300 mg%,  and 4 + ___  1,000 mg%.  Low grade proteinuria was 
defined as  1+-2  +, and high grade proteinuria was defined as >2  + (>100 rag%). 
Anti-DNA Antibodies.  Antibodies to native DNA were determined using a modification of 
the Farr technique (24). Native DNA from Escherichia coli labeled with 125I (Amersham Corp., 
Amersham, England) was added to 50 p~l of serum, diluted 1:10, and preincubated at 56°C for 
30 min to decrease  nonspecific binding. The specimens were  incubated for  1 h at 37°C, and 
then for  16 h at 4°C. An equal volume of 90% saturated ammonium sulfate (SAS) was added, 
and the precipitate was collected by centrifugation and counted in a gamma counter (Beckman 
Instruments, Inc.,  Fullerton, Calif.)  Results  were  expressed  as  arbitrary  binding units  as 
determined initially by reference standards (Amersham Corp.), and subsequently by standard- 
ized NZB/NZW sera.  Binding units (units per milliliter) were similar to percent DNA bound 
when counts bound by the 0 U/ml standard are subtracted from total bound counts. (10 U/ml 
=  8.4% DNA bound,  15  U  =  13.4%, 25  U  =  25.5%, 60  U  =  59.2%). Equal numbers of 
treated and control sera were measured in each assay. 
A group of 31  nonexperimental mice including BALB/c, C57BI/Ka, and young 3-mo-old 
NZB/NZW females had a mean (+  2 SD) anti-DNA binding equal to 7.3 U/ml +  7.9 U/ml. 
Values greater than 2 SD above the mean (>24 U/ml) in experimental mice were considered 
elevated above normal. 
Collection of Serum Samples.  Mice were bled at  the  initiation of the experiment and then 
monthly from the retro-orbital sinus. Blood was allowed to clot for 1 h, and serum was removed 
and stored at -20°C. 
Results 
Mice  Treated  With  TLI at 6 Mo of Age.  48 NZB/NZW  female mice, aged 5-7 mo 
(mean age  ~-  6.0 mo) were documented to have at  least low grade proteinuria. 7 of 
55  tested  showed  no  proteinuria  and  were  excluded  from  the  study.  Littermate 
animals were randomly allocated to treatment (24 animals) or control (24 animals) 
groups. During irradiation, both groups were taken from the housing area daily and 
anesthetized  whereas  only  the  treated  animals  were  placed  under  the  radiation 
machine. Both  groups were  housed  in the same area and given similar diets.  Mice 
were checked for proteinuria and bled monthly. When possible, kidneys were obtained 
after death for histology. 
NZB/NZW mice tolerated the irradiation extremely well and there were no deaths 
during irradiation in the treated group. During the irradiation period, mean weight 
loss of treated animals was 9% of total body weight compared to  7%  in the control 
group. An occasional irradiated animal developed transient diarrhea. All side effects 
cleared  rapidly  in  the  week  after  irradiation. To  date,  there  have  been  no  deaths 
directly attributable to the irradiation, and, one animal with tumor has been identified BRIAN L. KOTZIN AND SAMUEL STROBER  373 
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FIC.  1.  Effect of treatment on the survival of NZB/NZW mice up to  1 yr of age. &--A  -A, 
radiation group,  O---O~O, control group. Hatched area is the time period of irradiation. 
in both the irradiated and control groups. 
Survival.  Fig.  1 shows the improved survival rate in irradiated  NZB/NZW mice. 
By  1 mo after the initiation of irradiation, there were 4 deaths in the control group 
and no deaths in the treated group. At age 8 mo, (2 mo after irradiation) the difference 
in the survival of the two groups became statistically significant (P <  0.005 by Fisher's 
exact  test.)  The difference continued to widen so that by  12 mo of age, 2 of the 24 
treated  animals and  18 of the  24 control animals  had died  (P <  0.00001).  Neither 
death in the treated group was associated with significant prior proteinuria or clinical 
illness  characteristic  of the  NZB/NZW  kidney  disease.  Renal  histology  was  not 
available  in  these  two  mice  secondary  to  postmortem  autolytic  changes,  and  no 
obvious cause for death was found at autopsy. Of the 18 control group deaths,  16 had 
prior high grade proteinuria and characteristic clinical illness.  Renal histology avail- 
able from 10 of these animals showed extensive end-stage glomerular damage by light 
microscopy. 
Proteinuria.  Fig.  2  shows  a  significant  reduction  in  the  incidence  of high  grade 
proteinuria in the treated group by age 8 mo (2 mo after irradiation)  (P <  0.0001). 
The difference became even more apparent as the study progressed and by 12 mo of 
age, 75% of the control group had progressed through a stage of high grade proteinuria 
compared to <10% in  the irradiated  group. High grade proteinuria  present  in one 
animal in the treatment group at initiation of the study was suppressed by 2 mo after 
irradiation, and did not reappear through the duration of the study. 
Anti-DNA Antibodies.  Fig. 3 demonstrates the suppression of anti-DNA antibodies 
in  the  treated  group.  46%  of the  treated  group  initially  had  levels  of anti-DNA 
antibodies above normal  (>24 U/ml), but  by 2 mo after irradiation, only  17%  had 
elevated levels.  Treated mice had median values equal to 5 U/ml both at 7 and 8 mo 
of age and equal to  11 U/ml at 9 mo of age. In contrast, the control group showed a 
rise  in anti-DNA antibodies over this time period such that 60% were above normal 
by 2 mo (median  =  36 U/ml) and 75% were above normal by 3 mo after irradiation 
(median  =  44 U/ml). The treated group maintained their lowered levels through 12 
mo  of age.  The  levels  of antibody  in  treated  and  control  group  are  significantly 374  REVERSAL  OF  NZB/NZW  DISEASE  WITH  TOTAL  LYMPHOID  IRRADIATION 
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FIG.  2.  Effect of treatment on the cumulative progression to high grade proteinuria (:>2 +, >100 
mg%)  up to  1 yr of age. Mice that  died without high grade proteinuria are not included in the 
denominator after  their  point  of death.  Two  control  animals died  before  7  mo of age without 
proteinuria. Two treated animals also died without proteinuria, one at  10 mo and one at  12 mo of 
age. A--&--A, radiation group; C)--O----O, control group. 
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FIG.  3.  Effect of treatment on anti-DNA antibodies up to  1 yr of age. The data is expressed as 
percentage of mice with levels elevated above normal. The mean normal value (+ SD) was 7.3 U/ 
ml  +  7.9.  Values >2 SD above this mean (>24 U/ml) were considered elevated. The numbers in 
parentheses  are  the  median  values  in  units  per  milliliter  for  the  group  of mice  at  that  time. 
A--&-- a, radiation group; O  O  ©, control group. 
different at 8, 9, 10, and 11 mo of age (P <  0.01 by Wilcoxon rank test). A comparison 
after  11  mo  is  difficult  because  of the  small  number  of control  animals  remaining 
alive. 
Mice With Advanced Protemuria.  18  7-too-old  female  NZB/NZW  mice  were  selected 
for  advanced  proteinuria  (3 +  or 4 +)  and  placed  in  treatment  (12  animals)  or control 
(6  animals)  groups.  Several  mice  which  were  clinically  ill  (ascitic  or  wasted)  were BRIAN  L.  KOTZIN AND  SAMUEL STROBER  375 
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Fro.  4.  Effect of treatment on advanced NZB/NZW disease. The numbers in parentheses indicate 
the fraction of mice with high grade proteinuria of those alive at that time. A--~A,  radiation 
group; O  O--O, control group. 
included in the study. One animal in the control group died before the onset of the 
study and therefore is not included in the analysis. In this experiment, control mice 
were not anesthetized as a result of their poor clinical state. 
Fig. 4 shows the prolongation of survival and reversal of proteinuria in the treated 
group. All 5 control animals died within 6 wk of beginning the study, whereas 3 of 12 
irradiated  animals  died  during  this  time  period  (2  anesthetic deaths)  (P <  0.01). 
Thereafter,  the  nine  treated animals  remained  alive  for  more  than  4  mo  after 
irradiation. Several clinically ill mice actually showed clinical improvement during 
the irradiation period. At  1 mo after irradiation, 4 of the  10 remaining animals had 
reversal of high grade proteinuria and at 2 mo after irradiation, 7 of 9 animals had 
reversal of high grade proteinuria. Subsequently, high grade proteinuria reappeared 
in some of these animals. 
Discussion 
Many studies with NZB/NZW mice have begun treatment at an age (<4 mo) when 
the autoimmune disease has not yet been expressed (12, 13, 15, 18, 19, 21, 23). These 
studies  are  properly termed  prophylactic and  have  limited  application  to  human 
SLE. Some therapeutic studies used animals 4-5 mo old, when anti-DNA antibodies 
and gamma globulin deposition in the kidney are present but histologic glomerular 
damage and onset of proteinuria have not yet occurred (25,  16,  17, 20, 26). Various 
immunosuppressive and anti-inflammatory treatment regimens begun at the time of 
early disease can prevent proteinuria and renal death (12-23). 
Few  studies  have shown  actual  suppression  of disease  after the  development of 
proteinuria.  Continuous high dose, weekly cyclophosphamide has been effective in 376  REVERSAL OF  NZB/NZW DISEASE WITH TOTAL LYMPHOID IRRADIATION 
suppressing already present renal disease and prolonging survival when begun after 
the age of 5-6 mo (12,  13, 21, 22). In contrast to these studies, a  trial of combination 
therapy  with  cyclophosphamide,  azathioprine,  and  methylprednisolone  which  was 
markedly effective at 5 mo of age was unsuccessful in prolonging survival at 8 mo of 
age (20). When 8-mo-old mice were divided into high (23 +) and low (<2 +) proteinuria 
groups, only the low proteinuria animals showed a  response to therapy. Cyclosphos- 
phamide treatment has been associated with an increased tumor incidence in NZB/ 
NZW mice (12,  19,  2l,  23).  Another drug capable of suppressing NZB/NZW renal 
disease is the anti-viral agent, ribavirin (26).  NZB/NZW mice treated at 20 wk of age 
developed  high  grade  protenuria  and  then  lost  proteinuria  while  treatment  was 
continued.  In addition, survival of the mice was considerably prolonged. 
TLI is a  routine,  safe radiotherapy regimen used to treat  Hodgkin's disease  (27). 
Severe side effects are unusual  and all severe complications requiring hospitalization 
are <1%  (including infectious complications). No cases of acute leukemia have been 
observed  in  several  hundred  Hodgkin's disease  patients  treated  with  radiotherapy 
alone at  Stanford during the past  10 yr (28).  We have demonstrated  the ability of 
TLI to produce potent immunosuppression in humans and normal laboratory animals 
(1, 2), and therefore attempted to treat NZB/NZW disease. The experimental results 
show  that  NZB/NZW  hybrid  females  with  proteinuria  (aged  5-7  too)  had  no 
mortality and minimal (mean 9%) weight loss during the administration of 3,400 rad 
(TLI). Over 90% of the treated animals, but only 25% of the untreated controls were 
alive at  12 too. The treated group showed a  decrease in both proteinuria and anti- 
DNA antibodies.  TLI was  also  able  to  markedly prolong survival even  in  animals 
with advanced proteinuria such that 67% were alive at 11.5 mo of age. Although only 
one animal with a  tumor has been identified in both the treated and control groups, 
we are continuing  to follow the treated animals carefully for late tumor formation. 
The  mechanism  by  which  TLI  suppresses  NZB/NZW  disease  is  unknown  at 
present.  The  decrease  in  anti-DNA  antibodies  suggests  that  is  not  just  an  anti- 
inflammatory effect or a  local effect of radiation on the kidney.  It is  likely that  the 
potent immunosuppression induced by TLI plays an important role. There is consid- 
erable evidence that the qualitative aspects of the immunosuppression produced by 
TLI are unique  as compared to known  immunosuppressive drugs and single  dose, 
whole body irradiation. Only TLI causes long-lasting T  lymphopenia and B lympho- 
cytosis (2), and allows for the induction of tolerance to alloantigens and heterologous 
proteins (3, 6). The antigen specific tolerance has been shown to be dependent on the 
generation of suppressor T  cells (6).  Furthermore, there is evidence for the generation 
of antigen nonspecific suppressor cells shortly after TLI in the BALB/c mice (6). 
NZB/NZW  mice have an  age related  loss  in  the  induction  and  maintenance  of 
antigen-specific tolerance as well as a loss in antigen nonspecific T-suppressor function 
(9,  10).  These immune abnormalities may contribute to the immunopathology and 
expression of autoimmune disease in these mice (11).  We are presently investigating 
whether the suppression of NZB/NZW disease with TLI is associated with increased 
susceptibility to tolerization and the generation of suppressor T  cells. 
In  summary,  we  have  demonstrated  a  reversal  of  NZB/NZW  disease  without 
significant side effects with TLI. There is already an extensive experience with TLI in 
humans, and it has been well tolerated with only rare serious complications (27). This 
study suggests that TLI may have potential application to human SLE. BRIAN  L.  KOTZIN AND SAMUEL STROBER  377 
Summary 
NZB/NZW  mice spontaneously exhibit autoimmune disease similar to that seen in 
human  systemic lupus erythematosus  (SLE).  We demonstrated  that  total lymphoid 
irradiation  (TLI)  reversed  well  expressed  disease  in  6-too-old  NZB/NZW  females 
with  a  prolongation in survival, decrease in proteinuria, and  decrease in anti-DNA 
antibodies  as  compared  to  control  animals.  Few  side  effects  were  observed  in  the 
treated group. TLI also prolonged survival in animals with  advanced renal disease. 
These  findings suggest  that  TLI  may  have  application to  the  treatment  of human 
SLE. 
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